Aptevo Therapeutics(us:APVO)

1.99

+44.20%

Updated on 2025-04-03

Open:1.51
Close:1.99
High:2.64
Low:1.48
Prev Close:1.38
Volume:76.06M
Turnover:186.47M
Turnover Ratio:5214.84%
Shares:1.46M
MarketCap:2.90M
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-3019196374548.12%923
2024-03-312626430.39%1220
2023-12-3131439790.23%568
2023-09-3028340931623.57%547
2023-06-302692880412.31%235
2023-03-312988159612.18%3411
2022-12-313296336314.90%5414
2022-09-303086756617.04%367
dateorgNametotalratiochangeShareschangeRatio
2024-03-31Tower Research Capital Llc (Trc)13240.20%1014327.10%
2024-03-31Blackrock Inc.8900.13%-170-16.04%
2024-03-31Morgan Stanley1940.03%-64-24.81%
2024-03-31Qube Research & Technologies Ltd1000.01%100
2024-03-31Osaic Holdings, Inc.450.01%444400.00%
2024-03-31Jpmorgan Chase & Co430.01%0
2024-03-31Wells Fargo & Company/Mn360.01%-1-2.70%
2024-03-31Fifth Third Bancorp60.00%-1-14.29%
2024-03-31Pnc Financial Services Group, Inc.30.00%0
2024-03-31Truvestments Capital Llc20.00%0

About

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.
Address:2401 4th Avenue,Suite 1050

Market Movers